CYP2C19 and transient ischemic attack: In the present study, ticagrelor/aspirin therapy tended to have stronger platelet inhibition and more rapid onset in platelet inhibition compared with clopidogrel/aspirin therapy irrespective of CYP2C19 metabolizer status in patients with ischemic stroke and TIA.